As of 2025-07-11, the EV/EBITDA ratio of Mirati Therapeutics Inc (MRTX) is -5.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRTX's latest enterprise value is 3,859.11 mil USD. MRTX's TTM EBITDA according to its financial statements is -723.54 mil USD. Dividing these 2 quantities gives us the above MRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.0x - 12.7x | 11.2x |
| Forward P/E multiples | 12.1x - 19.1x | 12.1x |
| Fair Price | (121.11) - (127.51) | (116.47) |
| Upside | -306.3% - -317.2% | -298.4% |
| Date | EV/EBITDA |